Partner-hungry Hunter Immunology reverses into Australian listing
This article was originally published in Scrip
Hunter Immunology, a private developer of a vaccine to control bacterial infections in the airways of people with respiratory disease, is to begin trading on the Australian Securities Exchange on 4 April after carrying out a reverse merger into already listed Probiomics. The new entity, which is also raising A$2.4 million, will have a market capitalisation of around A$33 million. It will retain the name Probiomics initially but will soon be renamed Bioxyne.